The U.S. Justice Department will review plans by Alphabet Inc-owned Google to buy fitness tracker maker Fitbit Inc for possible antitrust issues, a source told Reuters on Tuesday.
French biopharmaceutical company hopes to become first to get approval of treatment for liver disorder that affects up to 30 million Americans Continue reading… …read more […]
U.S. President Donald Trump has days to decide whether to impose tariffs on nearly $160 billion in Chinese consumer goods just weeks before Christmas, a move that could be unwelcome in both the United States and China.
Independent experts to the U.S. Food and Drug Administration on Tuesday voted against Correvio Pharma Corp’s drug to correct irregular rhythm in the upper chambers of the heart in adult patients, the latest setback to the company’s efforts to market a potential blockbuster in the country. The panel voted 11-2 against approving the drug, Brinavess, citing serious safety risks, including low blood pressure and irregular rhythm in the lower heart chambers, and deaths during the trials. “It clearly has benefit but it does have risk,” said panel member Dr. Barry Davis of the University of Texas School …read more […]
Senate Democratic leader Chuck Schumer said on Tuesday he would wait to see the written form of the U.S. Mexico Canada trade pact before making a determination on it.
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […] …read more […]
Wall Street’s main stock indexes were little changed on Tuesday, hovering near record highs, as investors awaited concrete news on whether U.S. tariffs on Chinese imports would take effect on Dec. 15, a potential turning point in the two countries’ trade dispute that has convulsed markets.
Federal Reserve Chair Jerome Powell has taken a glass-half-full view of the U.S. economy but the trouble may be that the glass has gotten smaller and has a few cracks.
Top officials from Canada, Mexico and the United States signed a fresh overhaul of their quarter-century-old regional trade pact on Tuesday that aims to improve enforcement of worker rights and hold down prices for biologic drugs by eliminating a patent provision.
Senate Majority Leader Mitch McConnell said on Tuesday the U.S. Senate would not take up the USMCA trade deal next week before congressional recess.
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […] …read more […]
The drug stock is ripe for a short squeeze, too …read more […]
Independent experts to the U.S. Food and Drug Administration on Tuesday voted against Correvio Pharma Corp’s drug to correct irregular rhythm in the upper chambers of the heart in adult patients. Brinavess, currently available in 41 countries including the European Union and Canada, aims to restore normal heart rhythm in patients experiencing erratic rhythm due to a condition known as atrial fibrillation, or AFib. …read more […]
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds’ top 3 stock picks returned 41.7% this year and beat […] …read more […]
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like… …read more […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
